Loss of diversity within Mycoplasma bovis isolates collected in France from bovines with respiratory diseases over the last 35 years

Becker, Claire; Thibault, François M.; Arcangioli, Marie-Anne; Tardy, Florence

doi:10.1016/j.meegid.2015.04.019

Cited by 46 publications

(109 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Isolates were grown in PPLO broth, modified as previously described (26), at 37°C in 5% CO 2 . Each isolate was subtyped by single-locus sequence typing (using a 486-bp region of the polC gene), which has been shown to provide relevant typing results (8). Clustering of the isolates was confirmed by applying the MLST scheme of Register et al (21).…”

Section: Methodsmentioning

confidence: 99%

“…These isolates were then subtyped by sequencing of the polC locus as previously described (8). As expected, all old strains and PG45…”

Section: An Initial Set Of 31 Clinical Isolates Of M Bovis Either Omentioning

confidence: 99%

“…One of the recent isolates (strain 15527) belonged to ST3, an uncommon subtype characterized by 16 SNPs (see Table S1 in the supplemental material) (8).…”

Section: An Initial Set Of 31 Clinical Isolates Of M Bovis Either Omentioning

confidence: 99%

“…This restricted use could have limited the acquisition of resistance in France. Moreover, we recently demonstrated that recent M. bovis isolates from France belong to the same unique subtype and suggested that this monoclonal spread on a country-wide scale could be linked to the acquisition and selection of multiresistance through therapeutic practices and prevention strategies (8). The reason for fluoroquinolones being spared in this selection process has yet to be clarified.…”

mentioning

confidence: 99%

“…In addition, clinical isolates were subtyped by single-locus sequence typing (8) and multilocus sequence typing (MLST) (21), and their ability to become resistant to fluoroquinolones through mutations of their QRDRs was explored in vitro. The results were analyzed in order to determine whether the process and rapidity of developing resistance to fluoroquinolones under selective pressure may differ by subtype.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Alterations in the Quinolone Resistance-Determining Regions and Fluoroquinolone Resistance in Clinical Isolates and Laboratory-Derived Mutants of Mycoplasma bovis: Not All Genotypes May Be Equal

Khalil

Becker

Tardy

2016

Appl Environ Microbiol

Self Cite

View full text Add to dashboard Cite

Mycoplasma bovis is considered a major contributor to respiratory diseases in young cattle. Resistant M. bovis isolates have increasingly been reported worldwide due to extensive use of antimicrobials to treat bovine pneumonia. The frequency of isolates resistant to fluoroquinolones varies considerably from one country to another. The MICs of isolates collected in France have only increased from "very low" to "low." The present study was conducted to investigate whether alterations in the quinolone resistance-determining regions (QRDRs) could account for this slight modification in susceptibility. No correlation between QRDR alterations and increased MICs was evidenced in clinical isolates. In addition, all clinical isolates were subtyped, and the tendencies of the different sequence types to develop resistance through mutations in QRDRs under selective pressure in vitro were examined. In vitro, 3 hot spots for mutations in QRDRs (position 83 in GyrA and positions 80 and 84 in ParC) were associated with a high level of resistance when cumulated. We showed that the point mutations in the QRDRs observed in vitro were different (in location and selection rapidity) between the different subtypes. Our in vitro observations were corroborated by the recent detection of a clinical isolate highly resistant to fluoroquinolones (MIC > 16 g/ml) and belonging to the subtype which easily accumulates QRDR alterations in vitro. The current increased prevalence of this subtype in clinical isolates highlights the urgent need to control fluoroquinolone usage in veterinary medicine. Mycoplasma bovis is a wall-less bacterium responsible for severe infections in cattle, including pneumonia, mastitis, arthritis, and otitis (1). In young cattle, it is now recognized as a major contributor to economic losses associated with bovine respiratory diseases (BRD). The infection pressure of BRD usually peaks 2 to 3 weeks after calves are mingled in fattening units following transportation from their respective birth farms (2). Since no efficient vaccines are available and licensed for use outside the United States (3), efforts to control M. bovis infections often rely on antimicrobial treatments, administered either prophylactically or in the early stages of the disease. Antimicrobials used for the treatment or prevention of BRD usually include broad-spectrum cephalosporins (cefquinome and ceftiofur), extended-spectrum fluoroquinolones (enrofloxacin, danofloxacin, and marbofloxacin), florfenicol, and long-lasting macrolides (tulathromycin, gamithromycin, and tildipirosin) (4). This extensive use of antibiotics has predictably resulted in an increase in resistant isolates over time. In France, it was recently shown that contemporary M. bovis strains had become significantly less susceptible than archival strains to 9 of the 12 antimicrobials tested (5). With regard to fluoroquinolones, the decrease in susceptibility was limited (only 1 dilution of the MIC), and no highly resistant isolates were observed in a set of more than 90 strains. This wa...

show abstract

Section: Methodsmentioning

confidence: 99%

“…These isolates were then subtyped by sequencing of the polC locus as previously described (8). As expected, all old strains and PG45…”

Section: An Initial Set Of 31 Clinical Isolates Of M Bovis Either Omentioning

confidence: 99%

“…One of the recent isolates (strain 15527) belonged to ST3, an uncommon subtype characterized by 16 SNPs (see Table S1 in the supplemental material) (8).…”

Section: An Initial Set Of 31 Clinical Isolates Of M Bovis Either Omentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Alterations in the Quinolone Resistance-Determining Regions and Fluoroquinolone Resistance in Clinical Isolates and Laboratory-Derived Mutants of Mycoplasma bovis: Not All Genotypes May Be Equal

Khalil

Becker

Tardy

2016

Appl Environ Microbiol

Self Cite

View full text Add to dashboard Cite

show abstract

MALDI‐TOF MS Analysis for Identification of Veterinary Pathogens from Companion Animals and Livestock Species

Timofte

Overesch

Spergser

2023

Microbiological Identification Using MALDI‐TOF and Tandem Mass Spectrometry

View full text Add to dashboard Cite

Comparison and optimisation of screening cutoff values for Mycoplasma bovis antibody ELISAs using serum from youngstock

2022

View full text Add to dashboard Cite

Background Mycoplasma bovis‐associated disease can cause tremendous production losses, welfare issues and high antimicrobial use. Therefore, screening cattle for M. bovis antibodies before entering the herd is a popular and possibly cost‐efficient way to reduce disease introduction. However, interpretation of results can be challenging due to variable accuracy between tests and populations. This study's objectives were to compare the diagnostic test accuracy of three commercially available M. bovis antibody ELISAs (ID‐screen, Bio K302 and Bio K432) and to explore optimal cutoff values for screening purposes. Methods A prospective diagnostic test accuracy study was performed on 170 serum samples from youngstock using Bayesian latent class modelling. Samples were categorised using manufacturer and generated cutoff values. Results Using the manufacturers' guidelines, ID‐screen, Bio K432 and Bio K302 showed 97.6%, 67.4% and 33.6% sensitivity, and 78.8%, 97.6% and 99.1% specificity, respectively. Optimised cutoffs resulted in 94.8%, 82.6% and 78.3% sensitivity, and 94.2%, 92.5% and 79.4% specificity, respectively. Conclusions The highest diagnostic accuracy for detecting M. bovis antibodies was obtained by ID‐screen (≥110%). However, by adjusting cutoff values, the sensitivity of Bio‐X tests could be markedly increased, making these tests also applicable as screening tools. Limitations Interpretation needs to be careful as antibodies may be linked to both infectious and non‐infectious status.

show abstract

Loss of diversity within Mycoplasma bovis isolates collected in France from bovines with respiratory diseases over the last 35 years

Cited by 46 publications

References 55 publications

Alterations in the Quinolone Resistance-Determining Regions and Fluoroquinolone Resistance in Clinical Isolates and Laboratory-Derived Mutants of Mycoplasma bovis: Not All Genotypes May Be Equal

Alterations in the Quinolone Resistance-Determining Regions and Fluoroquinolone Resistance in Clinical Isolates and Laboratory-Derived Mutants of Mycoplasma bovis: Not All Genotypes May Be Equal

MALDI‐TOF MS Analysis for Identification of Veterinary Pathogens from Companion Animals and Livestock Species

Comparison and optimisation of screening cutoff values for Mycoplasma bovis antibody ELISAs using serum from youngstock

Contact Info

Product

Resources

About